prochlorperazine edisylate
Generic: PROCHLORPERAZINE EDISYLATE·Brand: COMPAZINE, PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
prochlorperazine edisylate: sourced relationships with 1 company · 1 FDA decision.
prochlorperazine edisylate evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect prochlorperazine edisylate to NEXS; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could prochlorperazine edisylate → NEXS affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| NEXUS BIOPHARMA INC (NEXS) Reported 2019-02-15 · Current development: unknownSource | Approved |
| NEXUS BIOPHARMA INC (NEXS) Reported 2019-02-15 · Current development: unknownSource | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with prochlorperazine edisylate?
prochlorperazine edisylate has dated SEC/FDA relationship records for NEXUS BIOPHARMA INC.
What is prochlorperazine edisylate's latest FDA decision?
The most recent tracked FDA decision for prochlorperazine edisylate is Approval for INDICATIONS AND USAGE To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation., dated February 15, 2019.